Reasons to be bearish
Spring 2017 SH's voted for 500% increase in authorized shares from 90m to 450m and a r/s of up to 1 for 25 with ratio to be set before Jan 30 2018. Classic small bio bull trap money printing dilution machine.
OS have gone from 30m to 125 m in a year, from 90m to 120m 10 days ago and another 5m in past days, 125m total.
There are approx 2 "retail share holder diluting" "tute position increasing" warrants overhanging each share of stock.
They have made strong gains towards issuing almost all the increased outstanding stock in only 9 months
A reverse split will NOT decrease the AUTH SHARES thus allowing the dilution machine to be reset and reused.
The r/s ratio must be set prior to jan 30 but the r/s can happen anytime before or AFTER that date, or never.
The stock is under a NYSE CURE PERIOD REVIEW which comes up Jan 20 to see if it will stay listed. There may be, according to older sec fillings, some amount of vestment that must be refunded ASAP from cash if NYSE delists to one investor.
Co sought 40m to start phase3 acne trails and failed, then tried for 17m and PIVOTED from acne to rosacea in USE OF FUNDS and failed. Then settled for 9.7m NET with the new pivot intact. Co has burned 1.4 m monthly in 2017.
Co most recent PR rehashes 11 month old PR virtually same content re attending a conference with 1 year old already presented info.
Co IR indicated co plans to do ROAD SHOW to investors to secure phase 3 funding. These investors are not MARGE in her RV retired in Arizona, these are bio savvy tutes they are already well aware of all the particulars of this co.
In the final tiny 9.7m offering a group of warrants tied to an award if phase 3 funding is secured indicates the Co has provided for almost 18 months to go out and secure that funding. Placing that product many years away from market, thats in extreme opposition to previous forward looking statements in 2017.
FOMX and DERM are both running 4 phase 3 topical acne cream phase 3's right now, well underway with well funded co's behind them, 2 each. Good chance one or BOTH of them may be approved and capture the market well before bpmx can attempt an entry with a similar product.
During the bpmx acne symposium bpmx medical spoke person STATED that FOMX will be approved and will capture market share over bpmx based on local temps and humidity due to oil versus water based.
Phase 3 requires approx 30 million dollars to execute PLUS the 1.4m per month while it is under way, about a year. 45+ million dollars. They have less than 10 right now.
That est is based on est given by bpmx at acne symposium and phase 3 trial sizing of derm and fomx trials currently underway
Co places int asset value at 1.1 million dollars, last nov mkt cap sunk to 7m when they pivoted from breast drug to acne.
Co recent pivot away from acne to rosacea has been UNDER PLAYED and not reported. Current OS and similar crash in mkt cap as last nov places stock at under 6 cents.
Current indications short of any REAL NEWS places this at risk of greater than 60% sudden devaluation, similar slides have happened REPEATEDLY since June.
BEARISH
AI
